Everolimus, an orally bioavailable mTOR inhibitor, was approved in 2013 for use in the treatment of TSC-related SEGAs and AMLs based on robust evidence from clinical trials demonstrating its efficacy in reducing tumor volume and delaying surgical interventions (Davies et al., 2017) [6]. This evidence concerns the gene MTOR and neoplasm.